Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.69 USD | -1.90% | -1.81% | +27.58% |
Financials (USD)
Sales 2024 * | 66.97M | Sales 2025 * | 78.82M | Capitalization | 883M |
---|---|---|---|---|---|
Net income 2024 * | -152M | Net income 2025 * | -129M | EV / Sales 2024 * | 13.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 11.2 x |
P/E ratio 2024 * |
-5.3
x | P/E ratio 2025 * |
-6.51
x | Employees | 267 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.31% |
Latest transcript on Ocular Therapeutix, Inc.
1 day | -1.90% | ||
1 week | -1.81% | ||
Current month | -0.18% | ||
1 month | +20.04% | ||
3 months | -43.44% | ||
6 months | +129.44% | ||
Current year | +27.58% |
Managers | Title | Age | Since |
---|---|---|---|
Donald Notman
DFI | Director of Finance/CFO | 64 | 17-09-24 |
Chief Tech/Sci/R&D Officer | - | 21-09-27 | |
Jeffrey S. Heier
CTO | Chief Tech/Sci/R&D Officer | 63 | 15-09-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Adrienne Graves
BRD | Director/Board Member | 69 | 23-07-09 |
Director/Board Member | 76 | 12-11-04 | |
Merilee Raines
BRD | Director/Board Member | 68 | 21-09-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 1,487 M€ | +7.77% | - | |
0.00% | 9 M€ | +9.86% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 5.7 | -1.72% | 4,217,394 |
24-05-30 | 5.8 | -1.19% | 1,422,283 |
24-05-29 | 5.87 | -1.01% | 1,484,600 |
24-05-28 | 5.93 | +2.33% | 1,712,862 |
24-05-24 | 5.795 | -0.09% | 1,277,079 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.58% | 881M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- OCUL Stock